about
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date[Aesthetic gluteal region reconstruction with a perforator artery flap].ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies.Cobimetinib and vemurafenib for the treatment of melanoma.Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.Enhancement of Customary Dermoscopy Education With Spaced Education e-Learning: A Prospective Controlled Trial.Metastatic melanoma of the ovary and circulating S100B.Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma.RASopathic comedo-like or cystic lesions induced by Vemurafenib: A model of skin lesions similar but not identical to those induced by dioxins (MADISH).[Melanoma mimicking Reed naevus].Percutaneous Cryotherapy for Treatment of Chondroblastoma: Early ExperienceReply to "Benign subungual epidermoid inclusions"[Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review]Seven Non-melanoma Features to Rule Out Facial MelanomaAssociation of subungual melanoma and subungual squamous cell carcinoma: A case seriesProtective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersPublisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersDermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil
P50
Q33887664-3DC93C0F-C072-4A36-8F45-38FD409E38FAQ34488957-2D1F918C-CC04-4AE9-9816-42AC50B517B9Q37307458-D03A49F6-0A46-4463-B49A-C726DEF91632Q38305320-F95F9AAA-BDFA-4D8A-9EAE-AD23A0A54B65Q38783292-9829BBE6-75B7-4324-A2BA-A4D847DE8044Q44436411-B84A6D2F-B5D9-4662-AC6C-80658BFC0710Q47321362-B2918898-1D77-4AF3-AF46-AFBBC3EED376Q48259761-3ED5F9A8-B938-4148-B620-4211F7F38186Q48517578-3E1478C8-9D90-40F0-BD1F-710651445B08Q48933312-42E4EF3D-A62E-4F9D-AD78-82177C22B610Q51612948-BA87CFE3-BAA2-4E9D-80D5-F013FD0D04E5Q51731730-B3D1403A-EC11-4831-B09A-E3C9A7FF7800Q54349459-DFF5E2FB-B5A7-4E85-82A3-847F1A082EABQ57456307-650D5067-9B2C-41FA-B996-57F556944997Q58603080-012BC92E-FD61-4196-B15F-E66ED8B18B4AQ87407630-0EC910F3-8554-4CAA-90F9-DCC85CBB8686Q88647188-987A8473-ADE5-4472-B1FC-627DF3E38BB6Q89071433-E1F7C3FD-597C-40C9-B080-70934887E5D9Q92129115-73CB276C-44F2-4E13-B9BF-568521C445DAQ92659388-E75D1BAE-9164-4B40-ABCC-38CDE40EB152Q92816830-5D21F9FD-EC2C-412B-B562-1742F41E1DC0
P50
description
investigador
@es
researcher
@en
name
A Boespflug
@en
type
label
A Boespflug
@en
prefLabel
A Boespflug
@en
P31
P496
0000-0002-2656-5144